TY - JOUR
T1 - Updates on Clinical Trials in Systemic Lupus Erythematosus
AU - Sharabi, Amir
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/7
Y1 - 2021/7
N2 - Purpose of Review: Because of the complexity of systemic lupus erythematosus (SLE), different approaches are undertaken while investigating potential therapeutic compounds to treat the disease. The purpose of this review is to summarize the results from recent clinical trials, which investigated different compounds for treating SLE. Recent Findings: Targeting B cells and type I interferons constitutes the major focus in recent clinical trials. The potential for therapeutic effects of small molecule inhibition such as JAK, Tyk, and Btk is now being investigated for treating SLE. The immunoregulation of T cell activation in SLE is studied using low-dose IL-2 and CD40 ligand inhibition. There are clinical trials that study bispecific antibodies, with binding specificities for 2 different target molecules related to T- and B-cell activation or to different aspects of B cell activation. An approach of combination treatment is also being studied. Summary: Clinical trials are underway and new treatment compounds for SLE are being anticipated.
AB - Purpose of Review: Because of the complexity of systemic lupus erythematosus (SLE), different approaches are undertaken while investigating potential therapeutic compounds to treat the disease. The purpose of this review is to summarize the results from recent clinical trials, which investigated different compounds for treating SLE. Recent Findings: Targeting B cells and type I interferons constitutes the major focus in recent clinical trials. The potential for therapeutic effects of small molecule inhibition such as JAK, Tyk, and Btk is now being investigated for treating SLE. The immunoregulation of T cell activation in SLE is studied using low-dose IL-2 and CD40 ligand inhibition. There are clinical trials that study bispecific antibodies, with binding specificities for 2 different target molecules related to T- and B-cell activation or to different aspects of B cell activation. An approach of combination treatment is also being studied. Summary: Clinical trials are underway and new treatment compounds for SLE are being anticipated.
KW - Clinical trials
KW - Immunosuppression
KW - Systemic lupus erythematosus (SLE)
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85109110489&partnerID=8YFLogxK
U2 - 10.1007/s11926-021-01014-w
DO - 10.1007/s11926-021-01014-w
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 34212269
AN - SCOPUS:85109110489
SN - 1523-3774
VL - 23
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 7
M1 - 57
ER -